CARYSIL.NS(CARYSIL.NS)
CARYSIL.NS
No analyst ratings available
No analyst price targets available for CARYSIL.NS
Analyst coverage may not be available for this symbol
No recent analyst actions
| Metric | FY2027E | FY2028E | FY2029E |
|---|---|---|---|
| Revenue Avg | $10.68B | $12.55B | $14.21B |
| Low | $10.59B | $12.26B | $13.98B |
| High | $10.84B | $12.70B | $14.40B |
| EBITDA Avg | $2.11B | $2.48B | $2.81B |
| Low | $2.09B | $2.42B | $2.76B |
| High | $2.14B | $2.51B | $2.85B |
| EBIT Avg | $1.65B | $1.94B | $2.20B |
| Low | $1.64B | $1.89B | $2.16B |
| High | $1.67B | $1.96B | $2.22B |
| Net Income Avg | $1.17B | $1.46B | $1.69B |
| Low | $1.12B | $1.41B | $1.65B |
| High | $1.20B | $1.52B | $1.72B |
| EPS Avg | $41.20 | $51.20 | $59.30 |
| Low | $39.25 | $49.49 | $58.04 |
| High | $42.32 | $53.27 | $60.33 |
| Analysts (Rev / EPS) | 3 / 3 | 4 / 4 | 2 / 1 |
| Metric | Q3 2026 | Q4 2026 | Q1 2027 |
|---|---|---|---|
| Revenue Avg | $2.70B | $2.60B | $2.68B |
| Low | $2.70B | $2.60B | $2.68B |
| High | $2.70B | $2.60B | $2.68B |
| EBITDA Avg | $534M | $513M | $530M |
| Low | $534M | $513M | $530M |
| High | $534M | $513M | $530M |
| EBIT Avg | $418M | $401M | $414M |
| Low | $418M | $401M | $414M |
| High | $418M | $401M | $414M |
| Net Income Avg | $310M | $296M | $293M |
| Low | $310M | $296M | $293M |
| High | $310M | $296M | $293M |
| EPS Avg | $10.90 | $10.40 | $10.30 |
| Low | $10.90 | $10.40 | $10.30 |
| High | $10.90 | $10.40 | $10.30 |
| Analysts (Rev / EPS) | 1 / 1 | 1 / 1 | 1 / 1 |